Trial
NCT04623996
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sumitomo Pharma America, Inc.
Collaborators
—
Condition
Anemia in Myelodysplastic Syndromes
Intervention
TP-0184
Why stopped
Due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome, this study was unable to enroll a sufficient patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-09